News articles about ACADIA Pharmaceuticals (NASDAQ:ACAD) have trended somewhat positive this week, Accern reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ACADIA Pharmaceuticals earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.2030733939808 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
- Commercialisation Of Biologics: Benchmarking Leading Players (bizjournals.com)
- Hot Mover to Watch: ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) – Alpha Beta Stock (alphabetastock.com)
- ACADIA Pharmaceuticals Inc. (ACAD) Short Interest Update (americanbankingnews.com)
- ACADIA Pharmaceuticals Inc., (NASDAQ: ACAD), Real Industry, Inc., (NASDAQ: RELY), Zynerba Pharmaceuticals, Inc … – Stocks In The News (press release) (tradingnewsnow.com)
- Acadia Pharmaceuticals: The Harmony Trial And Buyout Potential … – Seeking Alpha (seekingalpha.com)
Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) traded up $1.32 during midday trading on Wednesday, hitting $29.02. The company had a trading volume of 1,744,400 shares, compared to its average volume of 1,660,026. ACADIA Pharmaceuticals has a 1 year low of $24.31 and a 1 year high of $41.20.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.10. The firm had revenue of $35.58 million during the quarter, compared to analysts’ expectations of $32.03 million. ACADIA Pharmaceuticals had a negative return on equity of 67.68% and a negative net margin of 320.71%. The business’s revenue was up 571.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.61) EPS. research analysts anticipate that ACADIA Pharmaceuticals will post -2.42 earnings per share for the current year.
A number of equities analysts have weighed in on the company. Ladenburg Thalmann Financial Services reissued a “buy” rating and set a $50.00 price objective (up previously from $48.00) on shares of ACADIA Pharmaceuticals in a research note on Monday, October 2nd. Needham & Company LLC reissued a “buy” rating and set a $49.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Sunday, September 17th. Goldman Sachs Group reissued a “neutral” rating and set a $45.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Friday, October 6th. HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Wednesday, August 9th. Finally, Cowen reissued a “buy” rating and set a $46.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Tuesday, November 7th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have assigned a buy rating to the stock. ACADIA Pharmaceuticals has a consensus rating of “Buy” and an average target price of $47.44.
In other news, EVP Glenn Baity sold 37,500 shares of the stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $40.91, for a total transaction of $1,534,125.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 22.25% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “ACADIA Pharmaceuticals (ACAD) Getting Somewhat Positive News Coverage, Study Finds” was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://transcriptdaily.com/2017/11/30/acadia-pharmaceuticals-acad-getting-somewhat-positive-news-coverage-study-finds.html.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).
Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.